



U. of Oslo U. of Copenhagen Chinese U. of Hong Kong Norwegian U. of Science and Technology K.G. Jebsen Centre for Alzheimer's Disease Kavli Institute for Systems Neuroscience NO-Age NO-AD MIT-AD

The NO-Age and NO-AD Seminar Series 030

'Complement signaling and lipid metabolism in neuroinflammation and Alzheimer's disease'

by

Hui Zheng, Ph.D.

Huffington Center on Aging, Baylor College of Medicine, USA

at

14:00-15:00 (CET), Monday, 26th April 2021

Register in advance for this webinar:

https://uio.zoom.us/webinar/register/WN_Aqa09WLV RHKUV035fshuHw

Organizers:

Evandro F. Fang (UiO), Martin Vyhnálek (CBAS), Jon Storm-Mathisen (UiO), Menno P. Witter (NTNU), Lene Juel Rasmussen (KU), W.Y. Chan (CUHK)

Queries: e.f.fang@medisin.uio.no

Previous recorded talks are available here: <https://noad100.com/videos-previous-events/>

The organization of the seminar is supported by the program Validation of specific mitophagy biomarkers across Alzheimer's disease continuum under the KAPPA programme by Technology Agency of the Czech Republic T001000215. Funding by EEA and Norway Grants.



Name: Hui Zheng, Ph.D.
Institute: Baylor College of Medicine
Email: huiz@bcm.edu
Photo:

Speaker: Hui Zheng

Title: Complement signaling and lipid metabolism in neuroinflammation and Alzheimer's disease

Abstract:

Besides the pathological hallmarks of β -amyloid plaques and neurofibrillary tangles, Alzheimer's disease (AD) is accompanied by prominent neuroinflammation manifested by the chronic activation of microglia and astrocytes. Emerging genetic evidence provide strong support for a functional role of innate immunity and neuroinflammation in late-onset AD. We identified a complement C3 and C3a receptor signaling axis that governs neuron-immune signaling in the context of aging and AD. In addition, we uncovered a novel epoxy lipid metabolic pathway that becomes dysregulated in AD and show that targeting this pathway by small molecule inhibitors lead to potent anti-inflammatory and neuroprotective effects in AD mouse models, supporting the potential of these inhibitors as AD therapy.

Biography:

Dr. Zheng obtained her Ph.D. degree from Baylor College of Medicine in 1990. After a brief postdoctoral training at Baylor, she joined Merck & Co. where she began her research on Alzheimer's disease. She returned to Baylor as a faculty in 1999 and is currently the Director and Professor of the Huffington Center on Aging and Huffington Foundation Endowed Chair. Dr. Zheng's expertise is mouse genetics and she is a pioneer in utilizing sophisticated mouse models to probe the biology and pathophysiology of Alzheimer's disease. Dr. Zheng's current research is focused on the investigation of the autophagy-lysosomal pathway and neuron-immune interaction in AD and related disorders. Dr. Zheng has published over 100 papers. She is a recipient of the New Scholar Award from the Ellison Medical Foundation and the Zenith Award from the Alzheimer's Association.